Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
20
CTOR Quote, Financials, Valuation and Earnings
Last price:
$1.11
Seasonality move
:
0.9%
Day range:
$1.07 - $1.23
52-week range:
$0.55 - $6.19
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.69x
Volume:
2.1M
Avg. volume:
458.4K
1-year change:
-21.28%
Market cap:
$87M
Revenue:
--
EPS (TTM):
-$0.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CTOR
Citius Oncology, Inc.
|
-- | -- | -- | -- | $6.00 |
|
CTXR
Citius Pharmaceuticals, Inc.
|
-- | -$0.24 | -- | -84.9% | $6.00 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CTOR
Citius Oncology, Inc.
|
$1.11 | $6.00 | $87M | -- | $0.00 | 0% | -- |
|
CTXR
Citius Pharmaceuticals, Inc.
|
$1.25 | $6.00 | $23.1M | -- | $0.00 | 0% | -- |
|
GTBP
GT Biopharma, Inc.
|
$0.63 | $8.00 | $6.7M | -- | $0.00 | 0% | 59.35x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.09 | $0.85 | $137.4M | 1.83x | $0.80 | 0% | 2.12x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.24 | $7.00 | $8.2M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CTOR
Citius Oncology, Inc.
|
10.5% | 12.358 | 1.22% | 0.00x |
|
CTXR
Citius Pharmaceuticals, Inc.
|
2.81% | 4.871 | 7.37% | 0.12x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CTOR
Citius Oncology, Inc.
|
-- | -$4.9M | -- | -- | -- | -- |
|
CTXR
Citius Pharmaceuticals, Inc.
|
-$41.4K | -$8.8M | -57.79% | -58.36% | -- | -$5.4M |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Citius Oncology, Inc. vs. Competitors
-
Which has Higher Returns CTOR or CTXR?
Citius Pharmaceuticals, Inc. has a net margin of -- compared to Citius Oncology, Inc.'s net margin of --. Citius Oncology, Inc.'s return on equity of -- beat Citius Pharmaceuticals, Inc.'s return on equity of -58.36%.
Company Gross Margin Earnings Per Share Invested Capital CTORCitius Oncology, Inc.-- -$0.08 $36.2M CTXRCitius Pharmaceuticals, Inc.-- -$0.80 $69.4M -
What do Analysts Say About CTOR or CTXR?
Citius Oncology, Inc. has a consensus price target of $6.00, signalling upside risk potential of 440.54%. On the other hand Citius Pharmaceuticals, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 380%. Given that Citius Oncology, Inc. has higher upside potential than Citius Pharmaceuticals, Inc., analysts believe Citius Oncology, Inc. is more attractive than Citius Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTORCitius Oncology, Inc.0 0 0 CTXRCitius Pharmaceuticals, Inc.1 1 0 -
Is CTOR or CTXR More Risky?
Citius Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Citius Pharmaceuticals, Inc. has a beta of 1.509, suggesting its more volatile than the S&P 500 by 50.851%.
-
Which is a Better Dividend Stock CTOR or CTXR?
Citius Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology, Inc. pays -- of its earnings as a dividend. Citius Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTOR or CTXR?
Citius Oncology, Inc. quarterly revenues are --, which are smaller than Citius Pharmaceuticals, Inc. quarterly revenues of --. Citius Oncology, Inc.'s net income of -$5.4M is higher than Citius Pharmaceuticals, Inc.'s net income of -$9.2M. Notably, Citius Oncology, Inc.'s price-to-earnings ratio is -- while Citius Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology, Inc. is -- versus -- for Citius Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTORCitius Oncology, Inc.-- -- -- -$5.4M CTXRCitius Pharmaceuticals, Inc.-- -- -- -$9.2M
-
Which has Higher Returns CTOR or GTBP?
GT Biopharma, Inc. has a net margin of -- compared to Citius Oncology, Inc.'s net margin of --. Citius Oncology, Inc.'s return on equity of -- beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital CTORCitius Oncology, Inc.-- -$0.08 $36.2M GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About CTOR or GTBP?
Citius Oncology, Inc. has a consensus price target of $6.00, signalling upside risk potential of 440.54%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1170.25%. Given that GT Biopharma, Inc. has higher upside potential than Citius Oncology, Inc., analysts believe GT Biopharma, Inc. is more attractive than Citius Oncology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTORCitius Oncology, Inc.0 0 0 GTBPGT Biopharma, Inc.1 0 0 -
Is CTOR or GTBP More Risky?
Citius Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.
-
Which is a Better Dividend Stock CTOR or GTBP?
Citius Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTOR or GTBP?
Citius Oncology, Inc. quarterly revenues are --, which are smaller than GT Biopharma, Inc. quarterly revenues of --. Citius Oncology, Inc.'s net income of -$5.4M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Citius Oncology, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology, Inc. is -- versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTORCitius Oncology, Inc.-- -- -- -$5.4M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns CTOR or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Citius Oncology, Inc.'s net margin of -255.85%. Citius Oncology, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CTORCitius Oncology, Inc.-- -$0.08 $36.2M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CTOR or NBY?
Citius Oncology, Inc. has a consensus price target of $6.00, signalling upside risk potential of 440.54%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Citius Oncology, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Citius Oncology, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTORCitius Oncology, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CTOR or NBY More Risky?
Citius Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock CTOR or NBY?
Citius Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Citius Oncology, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTOR or NBY?
Citius Oncology, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Citius Oncology, Inc.'s net income of -$5.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Citius Oncology, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology, Inc. is -- versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTORCitius Oncology, Inc.-- -- -- -$5.4M NBYNovaBay Pharmaceuticals, Inc.2.12x 1.83x $521K -$1.3M
-
Which has Higher Returns CTOR or PTN?
Palatin Technologies has a net margin of -- compared to Citius Oncology, Inc.'s net margin of --. Citius Oncology, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CTORCitius Oncology, Inc.-- -$0.08 $36.2M PTNPalatin Technologies-- -- -- -
What do Analysts Say About CTOR or PTN?
Citius Oncology, Inc. has a consensus price target of $6.00, signalling upside risk potential of 440.54%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Citius Oncology, Inc., analysts believe Palatin Technologies is more attractive than Citius Oncology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTORCitius Oncology, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is CTOR or PTN More Risky?
Citius Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock CTOR or PTN?
Citius Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTOR or PTN?
Citius Oncology, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Citius Oncology, Inc.'s net income of -$5.4M is higher than Palatin Technologies's net income of --. Notably, Citius Oncology, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTORCitius Oncology, Inc.-- -- -- -$5.4M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns CTOR or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Citius Oncology, Inc.'s net margin of --. Citius Oncology, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital CTORCitius Oncology, Inc.-- -$0.08 $36.2M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About CTOR or TOVX?
Citius Oncology, Inc. has a consensus price target of $6.00, signalling upside risk potential of 440.54%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2797.35%. Given that Theriva Biologics, Inc. has higher upside potential than Citius Oncology, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Citius Oncology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTORCitius Oncology, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is CTOR or TOVX More Risky?
Citius Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock CTOR or TOVX?
Citius Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTOR or TOVX?
Citius Oncology, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Citius Oncology, Inc.'s net income of -$5.4M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Citius Oncology, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTORCitius Oncology, Inc.-- -- -- -$5.4M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
